Cerity Partners LLC Janux Therapeutics, Inc. Transaction History

Cerity Partners LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$7.93 - $49.75 $313,250 - $1.97 Million	-39,502 Reduced 64.83%	21,431 $806,000
Q4 2023 Jan 26, 2024	BUY	$5.85 - $11.7 $356,458 - $712,916	60,933 New	60,933 $653,000
Q2 2023 Aug 14, 2023	BUY	$11.08 - $15.92 $675,137 - $970,053	60,933 New	60,933 $723,000
Q3 2022 Nov 10, 2022	SELL	$10.82 - $16.84 $486,900 - $757,800	-45,000 Reduced 29.81%	105,933 $1.43 Million
Q4 2021 Feb 14, 2022	BUY	$15.44 - $27.32 $2.33 Million - $4.12 Million	150,933 New	150,933 $2.98 Million

160

37.2M

70.4K

101K

Ticker JANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,663,000
Market Cap $2.27B
Description
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...

Get notified when there are updates to the investment portfolio of Cerity Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Cerity Partners LLC with notifications on news.